Are the New ACC/AHA Guidelines for Lipids Appropriate for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Are the New ACC/AHA Guidelines for Lipids Appropriate for People With Diabetes?

SAN FRANCISCO, CA--(Marketwired - Jun 13, 2014) - New guidelines for the treatment of high cholesterol are not appropriate for people with type 2 diabetes -- or are they? Two researchers will debate the topic at a symposium to be held on Tuesday, June 17, at the American Diabetes Association's 74 th Scientific Sessions ® .

At issue are the newest guidelines issued jointly by the American College of Cardiology and American Heart Association in November 2013. Previous guidelines for treating people with high cholesterol were based upon cutpoints for low-density lipoprotein (LDL) cholesterol levels (the so-called "bad" cholesterol). People whose cholesterol levels hit those cutpoints were asked to initiate dietary changes, and, if that failed to lower levels sufficiently, statin therapy was recommended.

The new guidelines divide patients into four groups for whom statin treatment is recommended: individuals with cardiovascular disease; individuals with LDL cholesterol (LDL-C) levels higher than 190 mg/dL; individuals with diabetes, between the ages of 40-75, with LDL-C levels 70-189 mg/dL; and individuals without diabetes or cardiovascular disease, with LDL-C 70-189 mg/dL, and an estimated risk of cardiovascular disease greater than 7.5 percent. There are no specific target levels for lowering cholesterol, only the recommendation that statins be used to reduce it.

Under the new guidelines, the vast majority of people with type 2 diabetes would be recommended for statin therapy. But is that the right call?

Robert H. Eckel, MD, Professor of Medicine and Charles A. Boettcher Chair in Atherosclerosis at the University of Colorado, Anschutz Medical Campus, says, "Yes. Almost all people with diabetes should be on a statin. That's what the evidence tells us. You may not like the new guidelines, but these are evidence-based and this is what the evidence says."

Henry Ginsberg, MD, Irving Professor of Medicine and Director of the Irving Institute for Clinical and Translational Research at Columbia University, disagrees. "The guideline committee used the evidence-based construct much too narrowly," he said.

Ginsberg explained that he agreed with the recommendation to examine a person's risk for cardiovascular disease as well as their cholesterol level when determining whether to prescribe a statin. But he did not agree with the removal of target LDL cholesterol goals once a person is being treated with medication, or with the lack of recommendations for additional or alternative therapies.

"There are people who can't take a high dose of a statin, or who won't respond as well to a high dose," he said. "In that case, you should be adding another medication. The new guidelines try to make it too simple."

Ginsberg said the new guidelines actually ignore evidence that shows the lower a patient's LDL-C level, the better. "How do you get to those lower levels if statins alone aren't enough?" he asked. "You add a non-statin."

But Eckel said that exceptions, which often come up in patients with diabetes, are addressed in the new guidelines by suggesting that physicians make a judgment call. "It should be an educated judgment, though, based on an understanding of the increased risk of heart disease and stroke for people with diabetes."

The American Diabetes Association recommends that people with diabetes keep LDL-C levels at or below 100 mg/dL, or under 70 mg/dL if they also have cardiovascular disease. The Association recommends using high-dose statin therapy to reach those goals.

Ginsberg said he agrees with the Association's present guidelines, noting that they are based on a wealth of data that includes, but is not restricted to, randomized clinical trials.

The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org . Information from both these sources is available in English and Spanish .

Contact: Christine Feheley (703) 253-4374 Angela Murray (703) 549-1500, ext. 3425 News Room: June 13-17, 2014 Room S-252 (415) 978-3636

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI and Workforce Transformation: Zellis Connect 2026

Updated Category News Views 2

AI Transformation: Hard Reality or Strategic Opportunity? The future of work. That’s what everyone’s buzzing about lately, isn’t it? AI poised to shake every nook and cranny. You're either riding the wave or getting crushed by it. It’s no longer some distant prospect—the challenge is right here, now. Come September 23, Zellis Connect 2026 is plunging headfirst...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 4

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Early Orders Key for Custom Kids' Gifts This Season

Updated Category News Views 0

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

Continue Reading
Nuix Leverages AI for Transformative Legal Review

Updated Category News Views 1

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Continue Reading
XiamenAir Takes Off with Fujian-London Link

Updated Category News Views 3

A New Dawn for Fujian Travelers Here's a nugget to chew on: XiamenAir's first-ever direct flight from Xiamen to London had its moment in the spotlight. This isn't just another intercontinental flyby—it's a game-changer for folks in Fujian looking to hop across the pond without the layover hassle. With Flight MF821 touching down in Heathrow early on September 6th, this...

Continue Reading
BYD's Chip Mastery Amid China's Auto Supply Tensions

Updated Category News Views 7

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Continue Reading
PBC 2026 Forum: Philanthropic Titans Collide in HK

Updated Category News Views 0

A Decade of Philanthropic Discourse The winds of change blew through Hong Kong’s West Kowloon Cultural District today, marking the tenth anniversary of the PBC 2026 forum—an event that’s got everyone from government bigwigs to sports icons chatting. Convened by The Hong Kong Jockey Club Charities Trust alongside the Institute of Philanthropy, this two-day journey is...

Continue Reading
SKF's Automotive Arm Set for Stockholm Debut in Dec

Updated Category News Views 0

The Big Spin-Off Play: SKF Vertevo So, SKF is at it again, pushing their Automotive business out the door as a newly minted public company—SKF Vertevo—on the horizon. It's like watching a mother bird kick the fledgling out of the nest. The Board's cooked up this spin-off strategy, and they're eyeing the Nasdaq Stockholm as the breeding ground, with the gears all set...

Continue Reading
La Compagnie Unveils NYC-Düsseldorf Flight Plans

Updated Category News Views 2

A new chapter is unfolding in the skies over the Atlantic. La Compagnie is gearing up to connect New York to Düsseldorf with a direct, all-business-class flight starting in Spring 2027. This move is ambitious, tapping into the bustling economic energy present across the North Rhine-Westphalia region—an economic powerhouse littered with U.S.-affiliated businesses. A...

Continue Reading
Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Updated Category News Views 0

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Continue Reading

Top 5 Most Recently Viewed Articles

HFCL's Eka™ Fiber Revolutionizes Telecom Connectivity in Europe

Updated Category News Views 150

HFCL Launches Eka™ Fiber at the FTTH Conference 2025 HFCL Limited, a global pioneer in next-generation telecommunications solutions, has unveiled its innovative Eka™ Optical Fiber at the FTTH Conference 2025. Designed in collaboration with European telecom companies, this groundbreaking fiber aims to bridge the connectivity gaps within rural and urban landscapes of...

Continue Reading
CAI Software Expands Its Manufacturing Throne with PlanetTogether

Updated Category News Views 7

CAI Software's Ambitious Move Who would've guessed, folks? Just another day in the volatile tech landscape, and we see CAI Software splashing the cash to snag PlanetTogether. This isn't just a move to puff up their chest; it's a strategic addition, placing some real weight behind their manufacturing software game. New Horizons with Advanced Planning and Scheduling...

Continue Reading
Artera Expands Its Prostate Test Availability with New License

Updated Category News Views 62

Artera Gains California Lab License to Offer Prostate Test Artera, a leader in artificial intelligence (AI) for cancer diagnostics, recently announced the attainment of its official laboratory license from the California Department of Public Health (CDPH). This important step opens the door for Artera to provide its revolutionary ArteraAI Prostate Test across one of the...

Continue Reading
Bicara Therapeutics Achieves Breakthrough Therapy Milestone for Cancer Treatment

Updated Category News Views 121

Bicara Therapeutics Updates on Financial Results and Business Strategy Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, reports its financial outcomes for the third quarter of 2025 alongside strategic business insights. One of the most noteworthy achievements this quarter is the FDA granting Breakthrough Therapy Designation for...

Continue Reading
ScanTech AI Takes Significant Step with Quarterly Filing Update

Updated Category News Views 179

ScanTech AI's Quarterly Report Filing Details ScanTech AI Systems Inc. is pleased to announce that it has successfully filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC). This filing is a vital step for the company as it aligns with Nasdaq Listing Rule 5250(c)(1), resolving a previous noncompliance issue stemming from a delayed...

Continue Reading